Michael Chambers (L) and John Ballantyne

Dana­her strikes deal to buy boom­ing next-gen man­u­fac­tur­er Alde­vron for $9.6B

Life sci­ences con­glom­er­ate Dana­her Corp. $DHR has struck a deal to buy the fast-grow­ing Alde­vron, one of the world’s top man­u­fac­tur­ers of hot­ly sought-af­ter plas­mid DNA, mR­NA and re­com­bi­nant pro­teins for the bur­geon­ing world of vac­cine and drug­mak­ers push­ing some game-chang­ing tech­nolo­gies.

Buy­out talks set the stage for Dana­her to set­tle on a $9.6 bil­lion cash pact to ac­quire the pri­vate Far­go, ND-based com­pa­ny — a key sup­pli­er for a dis­rup­tive new Covid vac­cine as well as a host of gene and cell ther­a­py and CRISPR gene edit­ing play­ers — found­ed by Michael Cham­bers and CSO John Bal­lan­tyne as a crew of 2 back in 1998.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.